SCHEMBL285427

SCHEMBL285427

NCCCS[C@H](N)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.45
RNPEP Q9H4A4 1/20 0.39
CPB2 Q96IY4 4/20 0.38
GABRR1 P24046 3/20 0.37
LMNA P02545 2/20 0.37
THRB P10828 2/20 0.37
BLM P54132 2/20 0.37
KMT2A Q03164 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
CYP1A2 P05177 2/20 0.37
GABRR3 A8MPY1 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
HDAC3 O15379 1/20 0.37
GABBR2 O75899 1/20 0.37
GABRA1 P14867 1/20 0.37
TSHR P16473 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4955447 0.80 EPHX1 (0.46) THRBBLM
SCHEMBL1313408 0.79 GGT1 (0.41) GSRCPB2THRBBLMNFKB1
SCHEMBL20978334 0.74
SCHEMBL4949366 0.74
SCHEMBL28364927 0.74 BHMT (0.48) GSRLMNAKMT2ACYP1A2GABRP
Hydrochloric Acid SCHEMBL5653794 0.74 EPHX1 (0.44) GSRRNPEPCPB2GABRR1LMNA
SCHEMBL5969702 0.72 CPB1 (0.56) GSRRNPEPCPB2GABRR1LMNA
SCHEMBL1681277 0.71 GSR (0.35) GSRRNPEPCPB2GABRR1LMNA
SCHEMBL11737971 0.70 GSR (0.34) GSRRNPEPCPB2GABRR1LMNA
SCHEMBL3190291 0.70 GSR (0.34) GSRRNPEPCPB2GABRR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2026-02-17 US claimed
US-20260028375-A1 POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES ETH ZUERICH (CH) 2026-01-29 US claimed
EP-3833676-B1 POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES ETH ZUERICH (CH) 2025-05-28 EP claimed
US-20240287143-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Universität Zürich (CH) 2024-08-29 US claimed
EP-4295866-A2 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Virometix AG (CH) 2023-12-27 EP claimed
EP-3638284-B1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIROMETIX AG (CH) 2023-08-30 EP claimed
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2023-06-20 US claimed
US-11602107-B2 Graft-mediated hybridisation of monocotyledonous plants CAMBRIDGE ENTERPRISE LIMITED (GB) 2023-03-14 US claimed
US-20220267379-A1 NOVEL INHIBITORS OF KALLIKREIN PROTEASES AND USES THEREOF UNIVERSITÉ PARIS CITÉ (FR) 2022-08-25 US claimed
EP-3999530-A1 NOVEL INHIBITORS OF KALLIKREIN PROTEASES AND USES THEREOF ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2022-05-25 EP claimed
US-20180117082-A1 ANTIFUNGAL COMPOSITION/TREATMENT THE UNIVERSITY OF NOTTINGHAM (GB) 2018-05-03 US claimed
EP-3288962-A1 NOVEL INHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA) Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) 2018-03-07 EP claimed
EP-3273780-A1 ANTIFUNGAL COMPOSITION/TREATMENT The University of Nottingham (GB) 2018-01-31 EP claimed
WO-2017049213-A1 METHODS AND COMPOSITIONS FOR GENOMIC TARGET ENRICHMENT AND SELECTIVE DNA SEQUENCING PetaOmics, Inc. (US) 2017-03-23 WO claimed
WO-2016174103-A1 NOVEL INHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA) Ecole polytechnique fédérale de Lausanne (EPFL) (CH) 2016-11-03 WO claimed
WO-2016151293-A1 ANTIFUNGAL COMPOSITION/TREATMENT THE UNIVERSITY OF NOTTINGHAM (GB) 2016-09-29 WO claimed
US-20130225412-A1 SILICON NANOCARRIER FOR DELIVERY OF DRUG, PESTICIDES AND HERBICIDES , AND FOR WASTE WATER TREATMENT SARDARI LODRICHE SOROUSH (IR) 2013-08-29 US claimed
EP-1412515-A2 TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS Genset (FR) 2004-04-28 EP claimed
WO-2002066672-A2 TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS GENSET S.A. (FR) 2002-08-29 WO claimed
US-4401658-A VACCINE ADJUVANTS, IMMUNOSTIMULANTS RHONE-POULENC SANTE (FR) 1983-08-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIP, LNPEP, CSTB GSR 1013/4885RNPEP 12/4885CPB2 174/4885
US-20260028375-A1 POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES PHAX, TPX2, MLX GSR 2655/4885RNPEP 1698/4885CPB2 4144/4885
US-20240287143-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIP, QPCT, QPCTL GSR 1793/4885RNPEP 580/4885CPB2 1760/4885
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus CTH, VIP, CXCL10 GSR 864/4885RNPEP 593/4885CPB2 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.